Background: Levofloxacin is a third-generation fluoroquinolone that has several advantages over its (R) ofloxacin isomer. It is used to treat different types of infection, including urinary infection and prostatitis. Objective: A new HPLC method for the enantioselective separation of levofloxacin and its chiral impurity was developed and validated to improve the separation of the enantiomers of levofloxacin [impurity(R) and active principle (S)] by increasing the value of the resolution between the eutomer and the distomer. Method: Chromatographic separation was performed on a Prodigy ODS -2, 5 µm 4.6 × 150 mm column, with a gradient of buffer solution and methanol (80:20, v/v). A Box–Behnken design was considered when optimizing the enantioseparation involving the effects of many factors such as the concentration of d-phenylalanine, the pH of the buffer, the percentage of organic modifier in the mobile phase, the flow rate, the temperature of the column, and the type of column. Results: Chiral separation was achieved with an optimal resolution of 3.8. The method was successfully validated following the International Conference on Harmonization Q2 (R1) guideline, fulfilling the acceptance criteria for selectivity [no interference in the retention time of (S) levofloxacin and (R) levofloxacin], linearity (r ≥0.999 in the range 1.25–3.75 µg/mL for all enantiomers), and precision (RSD <2%). Accuracy was assessed by the application of the analytical method to an analyte of known purity, providing evidence for the usefulness of this monitoring system. Conclusions: The method was successfully used for the determination of levofloxacin impurity in raw material and pharmaceutical dosage forms. Highlights: The following method is accurate and robust to quantify and characterize the presence of levofloxacin impurity in raw material for pharmaceutical compounds.
Background: Accurate determination of active pharmaceutical ingredients and impurities is essential for ensuring the safety and effectiveness of medications. This study focuses on the validation of a high-performance liquid chromatography (HPLC) method for quantifying atorvastatin and its impurities, addressing a critical aspect of pharmaceutical analysis. Objective: The primary objective is to conduct a comprehensive validation study for the HPLC method, covering specificity assessment, response function establishment, and a detailed analysis of precision, trueness, and tolerance intervals. The emphasis is on demonstrating the method’s precision, accuracy, and stability-indicating capabilities across various concentrations and compounds. Methods: The HPLC method is validated through rigorous assessments, including specificity, response function establishment, and analyses of precision, trueness, and tolerance intervals. Induced degradation experiments are conducted to explore atorvastatin’s behavior under extreme conditions. Insights into the compound’s synthesis and degradation pathways are provided through a proposed mechanism for intramolecular esterification. Results: The results affirm the precision, accuracy, and stability-indicating capabilities of the validated HPLC method. The method effectively differentiates between atorvastatin and its impurities, showcasing its suitability for pharmaceutical quality control. Conclusions: The validated HPLC method emerges as a robust and reliable tool for atorvastatin analysis, contributing significantly to pharmaceutical research and quality control. Its application ensures the safety and efficacy of medications, reinforcing its role in pharmaceutical analysis. Highlights: This study not only validates a crucial HPLC method for atorvastatin analysis but also provides insights into the compound’s behavior under extreme conditions and its synthesis and degradation pathways. The validated method serves as a cornerstone in pharmaceutical research and quality control, ensuring medication safety and efficacy.
29 September 2025 in Journal of Electrochemical Science and Engineering
The accumulation of antiviral drugs, such as sofosbuvir (SOF), in aquatic environments raises growing concerns due to their persistence and potential ecological risks. This study addresses the need for effective degradation strategies by investigating the homogeneous electro-Fenton (EF) process in a Pt/carbon felt cell for the degradation and mineralization of SOF in an aqueous medium. A Box-Behnken design (BBD) was employed to optimize key operational parameters, including initial Fe2+ concentration, current intensity, and initial SOF concentration, targeting chemical oxygen demand (COD) removal as the main response. The model showed excellent predictability (R2 = 0.99), and the optimal conditions were identified as 400 mA current intensity, CSOF-0 = 0.1 mM, and CFe2+-0 = 0.1 mM. Under these conditions, 97% of SOF was degraded within 5 min, while complete mineralization was achieved within 5 h. Biodegradability tests revealed an increase in the BOD5/COD ratio to 0.41 after 2 h of electrolysis, indicating that the EF process can be effectively coupled with a biological treatment. The combined bio-electro-Fenton (bio-EF) approach successfully achieved complete mineralization, offering a cost-effective and sustainable strategy for the removal of recalcitrant pharmaceutical pollutants from water.